The effect of H1 receptor antagonist on rectal sensitivity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22721

Enrollment

Registered

2008-05-22

Start date

2008-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iriitabel Bowel Syndrome (IBS) Prikkelbaar Darm Syndroom (PDS)

Interventions

During 8 weeks patients with IBS will recieved a treatment with Fexofenadine, an H1 receptor antagonist, or placebo. The first 2 weeks 180 mg/day, then 6 weeks 360 mg/day. Before start and end of th

Eligibility

Inclusion criteria

Inclusion criteria: 1. 18-65 years 2. Patients have to meet the Rome Criteria for IBS

Exclusion criteria

Exclusion criteria: 1. Severe comorbidity like DM, kidneydiseases, liverdiseases cardiovasculair diseases. 2. Major abdominal surgery in history. 3. Use of antihistaminica, hypnotics or sedative medication 4. Pregnancy or breastfeeding 5. Indepandancy of alcohol

Design outcomes

Primary

Measure	Time frame
Effect of Fexofenadine on rectal sensitivity in IBS patients	—

Secondary

Measure	Time frame
Improvement of abdominal symptoms and qualty of life in IBS patients	—

Contacts

Public ContactB. Braak

Academic Medical Center Department of Gastroenteroloy and Hepatology

b.braak@amc.uva.nl+31 (0)20 5662061

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)